The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that offered some respite after recent setbacks.

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.